Document is current
Any future updates will be listed below
-
Authors
Ramage, Gordon https://orcid.org/0000-0002-0932-3514
Kean, Ryan
Rautemaa-Richardson, Riina https://orcid.org/0000-0002-1071-6040
Williams, Craig https://orcid.org/0000-0001-5002-6215
Lopez-Ribot, Jose L. https://orcid.org/0000-0003-1992-3270
- License Information
-
More Information
Article History
Accepted: 7 January 2025
First Online: 5 February 2025
Competing interests
: G.R. has received speaker fees from Gilead and Mundipharma. R.R.-R. has received speaker fees from Mundipharma, Astellas, Basilea, Gilead, Pfizer and Scynexis, and is the principal investigator for phase II clinical trials for Scynexis and F2G. The other authors do not declare any conflict of interest.
